The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Attention Score in Context
| Title |
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
|
|---|---|
| Published in |
Clinical Cancer Research, August 2023
|
| DOI | 10.1158/1078-0432.ccr-23-1272 |
| Pubmed ID | |
| Authors |
Deepti Telaraja, Yvette L Kasamon, Justin S Collazo, Ruby Leong, Kun Wang, Ping Li, Elyes Dahmane, Yuching Yang, Justin Earp, Manuela Grimstein, Lisa R Rodriguez, Marc R Theoret, Nicole J Gormley |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2023.
All research outputs
#7,083,998
of 25,990,612 outputs
Outputs from Clinical Cancer Research
#6,333
of 13,365 outputs
Outputs of similar age
#104,118
of 360,416 outputs
Outputs of similar age from Clinical Cancer Research
#67
of 139 outputs
Altmetric has tracked 25,990,612 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 13,365 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,416 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 139 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.